



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

The New Treatment Fund

**Medicines Recommended by NICE and AWMSG:
Health Board Formulary Status
(From 1 January 2018 to 31 December 2018)**

BACKGROUND

The Welsh Government launched the New Treatment Fund in January 2017. The fund provides an additional £16 million annually for health boards and trusts in Wales to support the faster introduction of new medicines recommended by the National Institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group (AWMSG).

The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable and certainly within 60 days of the publication of the decision. For NICE recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For AWMSG recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60 day timescale may be delayed because a Commercial Access Agreement (CAA) has not yet been agreed. In such circumstances this is indicated within the report. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, *The New Treatment Fund – Access to medicines recommended by NICE and AWMSG* (WHC [2017] 001).

A health board formulary is an official list of medicines which may be prescribed within the health board to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended between 1st January 2018 and 31st October 2018. All data in this report is as of 31 December 2018.

SOURCE OF INFORMATION

Across Wales, six of the seven health boards use the online “Inform” formulary software programme provided and maintained by the NHS Wales Informatics Service (NWIS). Abertawe Bro Morgannwg University Health Board (UHB) and Velindre NHS Trust (Velindre Cancer Centre) have separate formulary systems. Velindre NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This report has been compiled through a combination of an analysis of health board formularies and the submission of data and additional information from Chief Pharmacists.

Table 1. Formulary status and time elapsed since latest AWMMSG/NICE recommendation for New treatment Fund medicines (31 December 2018)

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Previous AWMMSG ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^#						
						ABMU	Aneurin Bevan	BCU	C&V	Cwm Taf	Hywel Dda	Powys
17/01/18	09/02/18	ID933 (TA510)		Daratumumab	Multiple Myeloma	-3	0	-1	34	46	4	27
18/01/18	16/03/18	ID1055 (TA507)		Vosevi	Hepatitis C	0	0	-36	34	31	11	20
01/02/18	01/02/18	ID523 (TA509)		Pertuzumab	Breast cancer	0	0	7	29	1	4	7
09/02/18		ID1020 (TA513)		Obinutuzumab	Lymphoma	0	0	27	34	3	27	27
09/02/18		ID878 (TA511)		Brodalumab	Psoriasis	-	0	27	34	17	27	27
12/02/18		ID591 (TA512)		Tivozanib	Renal cancer	2	3	24	56	14	24	24
15/02/18		ID56 (TA516)	577	Cabozantinib	Thyroid cancer	0	0	-	0	-	21	26
01/03/18	19/03/18	ID1102 (TA517)		Avelumab	Skin cancer (merkel cell)	0	1	-11	31	7	8	10
05/03/18		3557		Lopinavir/ritonavir	HIV	-	3	-	0	-	3	24
05/03/18		3343		Lacosamide	Epilepsy	-	3	-	0	-	3	24
05/03/18		2418		Symtuza	HIV	0	3	3	45	4	3	24
08/03/18		ID1051 (TA518)		Tocilizumab	Arteritis	0	0	0	42	1	19	21
16/03/18	16/03/18	ID1019 (TA519)		Pembrolizumab	Urothelial cancer	0	4	3	59	10	11	20
22/03/18		3397		Levodopa-carbidopa intestinal gel	Parkinson's disease	3	14	7	28	-	6	21
22/03/18		3627		Misoprostol	Induction of labour	0	14	7	0	5	7	21
09/04/18		ID970 (TA520)		Atezolizumab	Lung cancer	0	3	8	38	7	16	3
27/04/18	27/04/18	ID1209 (TA522)		Pembrolizumab	Urothelial cancer	0	3	3	55	3	3	3
03/05/18		ID1075 (TA521)		Guselkumab	Psoriasis	0	0	0	49	5	26	6
04/05/18		ID894 (TA523)		Midostaurin	Leukaemia	4	7	0	48	12	25	6
04/05/18		ID446 (TA526)		Arsenic trioxide	Leukaemia	0	0	-	0	-	-	6
04/05/18		ID1366 (TA524)	1255	Brentuximab vedotin	Lymphoma	-	-	0	0	-	25	6
14/05/18		ID809	1510	Interferon beta 1a	Multiple sclerosis	-	11	-	-	2	-	11
14/05/18		ID809		Interferon beta 1b (Extavia)	Multiple sclerosis	-	3	3	-	2	-	11
14/05/18		ID809		Glatiramer acetate	Multiple sclerosis	-	3	-	-	2	-	11
17/05/18		ID1327 (TA525)		Atezolizumab	Urothelial cancer	0	0	0	39	1	12	8
01/06/18	01/06/18	ID1041 (TA528)		Niraparib	Ovarian cancer	0	0	3	25	7	20	19
06/06/18	06/06/18	ID1349 (TA531)		Pembrolizumab	Lung cancer	-	-	-	-	-	-	14
13/06/18		3293		Icatibant acetate	Angioedema	0	1	0	50	5	8	7

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Previous AWMSG ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^#						
						ABMU	Aneurin Bevan	BCU	C&V	Cwm Taf	Hywel Dda	Powys
05/07/18		ID1059 (TA535)	976	Lenvatinib	Thyroid cancer	-	-	-	-	-	-	4
13/06/18		3233		Ranibizumab	Choroidal neovascularisation	0	1	0	50	5	8	7
13/06/18		700		Selexipag	Hypertension	0	1	0	50	5	8	7
22/06/18		ID937 (TA533)		Ocrelizumab	Multiple sclerosis	0	7	4	41	3	4	4
22/06/18		ID1048 (TA534)		Dupilumab	Atopic dermatitis	0	7	4	41	18	4	4
28/06/18		ID925 (TA536)		Alectinib	Lung cancer	0	4	19	35	1	27	11
29/06/18		ID1194 (TA537)		Ixekizumab	Psoriatic arthritis	0	3	18	34	4	27	10
05/07/18		ID1059 (TA535)	1416	Sorafenib	Thyroid cancer	-	4	-	28	11	8	4
12/07/18		ID910 (TA538)		Dinutuximab beta	Neuroblastoma	0	6	5	56	6	13	8
20/07/18		ID1224 (TA539)		Lutetium oxodotreotide	Neuroendocrine tumours	-	-	14	-	-	6	14
25/07/18	10/08/18	ID1062 (TA540)		Pembrolizumab	Lymphoma	0	6	7	55	6	7	20
23/07/18		2001		Dalbavancin	Skin infections	0	4	11	45	23	4	11
23/07/18		2037		Telotristat ethyl	Diarrhoea	0	4	11	45	23	8	11
23/07/18		1343		Ciprofloxacin	Ear infections	0	10	11	45	23	11	11
09/08/18		ID893 (TA541)		Inotuzumab ozogamicin	Leukaemia	7	7	7	28	7	8	21
23/08/18		ID1220 (TA543)		Tofacitinib	Psoriatic arthritis	0	0	15	42	11	6	7
24/08/18		ID1208 (TA542)		Cabozantinib	Renal cancer	0	0	14	41	10	5	6
05/09/18		ID1151 (HST8)		Burosumab	Hypophosphataemia	29	7	20	29	7	22	23
17/09/18		ID1226 (TA544)	1844	Dabrafenib	Melanoma	0	1	8	45	3	10	11
17/09/18		ID1226 (TA544)		Trametinib	Melanoma	0	1	8	45	3	10	11
20/09/18		3732		Octreotide	Neuroendocrine tumours	0	6	-	-	-	-	8
20/09/18		1988		Lanreotide	Neuroendocrine tumours	0	6	-	-	-	-	8
20/09/18		3582		Levonorgestrel	Contraception	-	4	6	42	6	7	8
01/10/18		ID1218 (TA547)		Tofacitinib	Ulcerative colitis	0	3	10	31	2	50	35
05/10/18		ID982 (TA545)		Gemtuzumab ozogamicin	Leukaemia	0	0	6	27	5	46	31

* Time to formulary addition from appraisal approval date should be within two months for AWMSG Health Technology Appraisals (including the orphan and ultra-orphan appraisal process), NICE Health Technology Appraisals and HSTs and cancer drugs. For NICE recommendations these should be following the first publication of the FAD or the FED for HSTs, and for AWMSG approvals following Welsh Government ratification.

[^] Number of days from latest AWMMSG/NICE approval statements and formulary status are data submitted by health board/trust. Where no number is provided this can generally be assumed to indicate that the medicine is “already on formulary” but for a different indication. However this is not always the case.

[#] The determination of formulary status is considered as the availability of the medicine to treat patients.

[¥] CAA (Commercial Access Agreement) Available Date information is provided by the all Wales Medicines Procurement Specialist Pharmacist






Key		On formulary. Where a number is stated this represents the number of days from AWMMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '['] indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMMSG/NICE approval.
		On formulary. However the number of days stated is outside of the 60 day timescale.
		Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMMSG/NICE approval to 31 December 2018.
		Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMMSG/NICE approval to 31 December 2018.
		Medicine is subject to a CAA. Stated number is the number of days from CAA availability to 31 December 2018. '-' indicates CAA is not yet available.

Table 2. Velindre Cancer Centre medicines status

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status					
					C+V	Powys*	ABMU*	Cwm Taf	ABUHB	VCC ONLY
01/02/2018	01/02/2018	ID523	Pertuzumab	Breast cancer	29	29	29	29	29	29
12/02/2018		ID591	Tivozanib	Renal cancer	56	56	56	56	56	56
15/02/2018		ID56	Cabozantinib	Thyroid cancer	0	0	0	0	0	0
01/03/2018	19/03/2018	ID1102	Avelumab	Merkel Cell	51	51	51	51	51	51
16/03/2018	16/03/2018	ID1019	Pembrolizumab	Urothelial cancer 2 nd line	46	46	46	46	46	46
09/04/2018		ID970	Atezolizumab 2 nd line	Lung Cancer	**	32	32	32	32	32
27/04/2018	27/04/2018	ID1209	Pembrolizumab	Urothelial cancer – platinum illegible	59	59	59	59	59	59
17/05/2018		ID1327	Atezolizumab	Urothelial cancer-	39	39	39	39	39	39
01/06/2018	01/06/2018	ID1041	Niraparib	Ovarian cancer	25	25	25	25	25	25
28/06/2018		ID925	Alectinib	Lung cancer	**	30	30	30	30	30
05/07/2018		ID1059 (TA535)	Lenvatinib	Thyroid cancer	0	0	0	0	0	0
05/07/2018		ID1059 (TA535)	Sorafenib	Thyroid cancer	0	0	0	0	0	0
20/07/2018		ID1224 (TA539)	Lutetium oxodotreotide	Neuroendocrine tumours	0	0	0	0	0	0
24/08/2018		ID1208 (TA542)	Cabozantinib	Renal cancer	0	0	0	0	0	0
17/09/2018		ID1226 (TA544)	Dabrafenib	Melanoma	45	45	45	45	45	45
17/09/2018		ID1226 (TA544)	Trametinib	Melanoma	45	45	45	45	45	45

*Powys and Abertawe Bro Morgannwg also commission cancer services from other cancer providers. These dates relate to the Powys and Abertawe Bro Morgannwg populations that Velindre Cancer Centre are commissioned for and there may be variability with dates from other cancer service providers.

** Cardiff and Vale UHB have their own lung service.

Key		On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '[']' indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval.
		On formulary. However the number of days stated is outside of the 60 day timescale.
		Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2018.
		Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2018.
		Medicine is subject to a CAA. Stated number is the number of days from CAA availability to 31 December 2018. '-' indicates CAA is not yet available.